Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Vivek Narayan, Ronac Mamtani, Stephen Keefe, Thomas Guzzo, S. Bruce Malkowicz, David J. Vaughn
Cancer Res Treat. 2016;48(3):1084-1091.   Published online 2015 Dec 2     DOI: https://doi.org/10.4143/crt.2015.405
Citations to this article as recorded by Crossref logo
Novel Tyrosine Kinase Targets in Urothelial Carcinoma
Javier Torres-Jiménez, Víctor Albarrán-Fernández, Javier Pozas, María San Román-Gil, Jorge Esteban-Villarrubia, Alfredo Carrato, Adriana Rosero, Enrique Grande, Teresa Alonso-Gordoa, Javier Molina-Cerrillo
International Journal of Molecular Sciences.2021; 22(2): 747.     CrossRef
Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Samira Bahrami, Bahram Kazemi, Hakimeh Zali, Peter C. Black, Abbas Basiri, Mojgan Bandehpour, Mehdi Hedayati, Amirhossein Sahebkar
Current Molecular Pharmacology.2020; 13(2): 150.     CrossRef
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer
Sharada Mokkapati, Sima P. Porten, Vikram M. Narayan, Amy H. Lim, Isuru S. Jayaratna, Beat Roth, Tiewei Cheng, Neema Navai, Matthew Wszolek, Jonathan Melquist, Ganiraju Manyam, Woonyoung Choi, Bradley Broom, Shanna Pretzsch, Bogdan Czerniak, David J. McCo
Molecular Cancer Research.2020; 18(6): 811.     CrossRef
Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity
Daniele Vinciguerra, Merel Jacobs, Stéphanie Denis, Julie Mougin, Yohann Guillaneuf, Gianpiero Lazzari, Chen Zhu, Simona Mura, Patrick Couvreur, Julien Nicolas
Journal of Controlled Release.2019; 295: 223.     CrossRef
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
Maristella Bianconi, Alessia Cimadamore, Luca Faloppi, Mario Scartozzi, Matteo Santoni, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Rodolfo Montironi
Therapeutic Advances in Urology.2019; 11: 175628721881537.     CrossRef
Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Joya-Rita Hindy, Tarek Souaid, Hampig Raphael Kourie, Joseph Kattan
Future Oncology.2019; 15(13): 1505.     CrossRef
Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody
Tadanobu Nagaya, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Deborah W. Knapp, Sophia N. Karagiannis, Judit Fazekas-Singer, Peter L. Choyke, Amy K. LeBlanc, Erika Jensen-Jarolim, Hisataka Kobayashi
Oncotarget.2018; 9(27): 19026.     CrossRef
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
Xiaobin Wang, Huihan Wang, Yongsheng Song
Oncology Letters.2018;[Epub]     CrossRef
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer
Consuelo Buttigliero, Marcello Tucci, Francesca Vignani, Giorgio V. Scagliotti, Massimo Di Maio
Cancer Treatment Reviews.2017; 54: 1.     CrossRef
The evolving genomic landscape of urothelial carcinoma
Alexander P. Glaser, Damiano Fantini, Ali Shilatifard, Edward M. Schaeffer, Joshua J. Meeks
Nature Reviews Urology.2017; 14(4): 215.     CrossRef
Prospects for precision therapy of bladder urothelial carcinoma
Nuno Vau, Metka Volavsek, Ana Blanca, Rodolfo Montironi, Maria R. Raspollini, Francesco Massari, Monica Cheng, Marina Scarpelli, Antonio Lopez-Beltran
Expert Review of Precision Medicine and Drug Development.2017; 2(5): 261.     CrossRef